EFFECT OF DISEASE AND DRUG-TREATMENT ON BLOOD SEROTONIN AND MONOAMINE-OXIDASE-B ACTIVITY IN PARKINSONS-DISEASE

被引：4
|
作者：
VANKEMPEN, GMJ [1 ]
JANJUA, R [1 ]
ROOS, RAC [1 ]
机构：
[1] LEIDEN STATE UNIV,ACAD HOSP,DEPT NEUROL,2333 AA LEIDEN,NETHERLANDS
来源：
CLINICAL NEUROLOGY AND NEUROSURGERY | 1995年 / 97卷 / 02期
关键词：
DRUG EFFECTS; 5-HYDROXYTRYPTAMINE; MONOAMINE OXIDASE; PARKINSONS DISEASE; SELEGILINE; SEROTONIN;
D O I：
10.1016/0303-8467(95)00011-8
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Serotonin (5-hydroxytryptamine, 5HT) content and monoamine oxidase (MAO) activity were determined in whole blood of patients with Parkinson's disease (PD) with and without drug treatment and compared with controls. From that comparison a significant reduction in platelet 5HT became apparent in PD. Selegiline, which was always used in combination with L-dopa, not only inhibited MAO activity, as expected, but it also appeared to induce an increase in 5HT content.
引用
收藏
页码：131 / 133
页数：3
相关论文
共 50 条
  • [1] PLATELET MONOAMINE OXIDASE-B ACTIVITY IN PARKINSONS-DISEASE - A REEVALUATION
    JARMAN, J
    GLOVER, V
    SANDLER, M
    TURJANSKI, N
    STERN, G
    JOURNAL OF NEURAL TRANSMISSION-PARKINSONS DISEASE AND DEMENTIA SECTION, 1993, 5 (01) : 1 - 4
  • [2] MONOAMINE-OXIDASE, DOPAMINE AND PARKINSONS-DISEASE
    ORELAND, L
    ACTA NEUROLOGICA SCANDINAVICA, 1991, 84 : 60 - 65
  • [3] ACTIVITY AND POLYMORPHISM OF MONOAMINE OXIDASE-B GENE IN IDIOPATHIC PARKINSONS-DISEASE
    HO, SL
    RAMSDEN, DB
    KAPADI, AL
    STURMAN, SG
    WILLIAMS, AC
    BIOGENIC AMINES, 1994, 10 (06) : 579 - 586
  • [4] WHOLE-BLOOD MONOAMINE-OXIDASE ACTIVITY IN PARKINSONS-DISEASE AND MULTIPLE SYSTEM ATROPHY PATIENTS
    KUIPER, MA
    KONINGS, CH
    BERGMANS, PLM
    WOLTERS, EC
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 1993, 117 (1-2) : 41 - 45
  • [5] HEREDITARY VARIATIONS IN MONOAMINE-OXIDASE AS A RISK FACTOR FOR PARKINSONS-DISEASE
    HOTAMISLIGIL, GS
    GIRMEN, AS
    FINK, JS
    TIVOL, E
    SHALISH, C
    TROFATTER, J
    BAENZIGER, J
    DIAMOND, S
    MARKHAM, C
    SULLIVAN, J
    GROWDON, J
    BREAKEFIELD, XO
    MOVEMENT DISORDERS, 1994, 9 (03) : 305 - 310
  • [6] THE RELEVANCE OF GLIAL MONOAMINE OXIDASE-B AND POLYAMINES TO THE ACTION OF SELEGILINE IN PARKINSONS-DISEASE
    YOUDIM, MBH
    RIEDERER, P
    MOVEMENT DISORDERS, 1993, 8 : S8 - S13
  • [7] PERIPHERAL-BLOOD CELL ACTIVITIES OF MONOAMINE OXIDASE-B AND SUPEROXIDE-DISMUTASE IN PARKINSONS-DISEASE
    CHECKOWAY, H
    COSTA, LG
    WOODS, JS
    CASTOLDI, AF
    LUND, BO
    SWANSON, PD
    JOURNAL OF NEURAL TRANSMISSION-PARKINSONS DISEASE AND DEMENTIA SECTION, 1992, 4 (04) : 283 - 290
  • [8] A RATIONALE FOR MONOAMINE-OXIDASE INHIBITION AS NEUROPROTECTIVE THERAPY FOR PARKINSONS-DISEASE
    OLANOW, CW
    MOVEMENT DISORDERS, 1993, 8 : S1 - S7
  • [9] CURRENT STRATEGIES IN THE DRUG-TREATMENT OF ADVANCED PARKINSONS-DISEASE - NEW MODES OF DOPAMINE SUBSTITUTION
    SCHELOSKY, L
    POEWE, W
    ACTA NEUROLOGICA SCANDINAVICA, 1993, 87 : 46 - 49
  • [10] PARKINSONS-DISEASE IN GENERAL-PRACTICE IN ALSACE-LORRAINE - CHARACTERISTICS AND STUDY OF DRUG-TREATMENT
    GROSS, M
    BAPSTREITER, J
    MASSINON, P
    REIS, J
    THERAPIE, 1992, 47 (02): : 149 - 151
12345